[{"address1": "1560 Trapelo Road", "city": "Waltham", "state": "MA", "zip": "02451", "country": "United States", "phone": "781 786 8230", "fax": "781 786 8866", "website": "https://www.dyne-tx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.", "fullTimeEmployees": 152, "companyOfficers": [{"maxAge": 1, "name": "Mr. John G. Cox M.B.A.", "age": 60, "title": "CEO, President & Director", "yearBorn": 1963, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Romesh  Subramanian Ph.D.", "age": 58, "title": "Co-Founder & Advisor", "yearBorn": 1965, "fiscalYear": 2020, "totalPay": 565170, "exercisedValue": 0, "unexercisedValue": 284933}, {"maxAge": 1, "name": "Mr. Richard William Scalzo M.B.A.", "age": 37, "title": "Senior VP and Head of Finance & Administration", "yearBorn": 1986, "fiscalYear": 2020, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. John  Najim M.B.A.", "title": "Chief Technical Officer", "fiscalYear": 2020, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Oxana  Beskrovnaya Ph.D.", "age": 62, "title": "Chief Scientific Officer", "yearBorn": 1961, "fiscalYear": 2020, "totalPay": 631076, "exercisedValue": 0, "unexercisedValue": 1167727}, {"maxAge": 1, "name": "Ms. Amy  Reilly", "age": 49, "title": "Senior VP and Head of Corporate Communications & Investor Relations", "yearBorn": 1974, "fiscalYear": 2020, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Daniel  Wilson", "age": 51, "title": "Senior VP & Head of Legal", "yearBorn": 1972, "fiscalYear": 2020, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Lucia  Celona", "age": 57, "title": "Chief Human Resource Officer", "yearBorn": 1966, "fiscalYear": 2020, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Debra  Feldman", "age": 52, "title": "Chief Regulatory Affairs Officer", "yearBorn": 1971, "fiscalYear": 2020, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Ashish  Dugar M.B.A., Ph.D.", "title": "Chief Medical Affairs Officer", "fiscalYear": 2020, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 8, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1727740800, "compensationAsOfEpochDate": 1609372800, "maxAge": 86400, "priceHint": 2, "previousClose": 33.39, "open": 33.16, "dayLow": 32.0, "dayHigh": 33.425, "regularMarketPreviousClose": 33.39, "regularMarketOpen": 33.16, "regularMarketDayLow": 32.0, "regularMarketDayHigh": 33.425, "beta": 1.054, "forwardPE": -10.240506, "volume": 686503, "regularMarketVolume": 686503, "averageVolume": 1256220, "averageVolume10days": 733830, "averageDailyVolume10Day": 733830, "marketCap": 3248976384, "fiftyTwoWeekLow": 6.4, "fiftyTwoWeekHigh": 47.45, "fiftyDayAverage": 36.8782, "twoHundredDayAverage": 31.225824, "currency": "USD", "enterpriseValue": 2495848704, "floatShares": 73748402, "sharesOutstanding": 100401000, "sharesShort": 8879434, "sharesShortPriorMonth": 6867616, "sharesShortPreviousMonthDate": 1724976000, "dateShortInterest": 1727654400, "sharesPercentSharesOut": 0.0884, "heldPercentInsiders": 0.0049799997, "heldPercentInstitutions": 1.12833, "shortRatio": 4.43, "shortPercentOfFloat": 0.105299994, "impliedSharesOutstanding": 103596000, "bookValue": 7.743, "priceToBook": 4.179259, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -257599008, "trailingEps": -3.58, "forwardEps": -3.16, "enterpriseToEbitda": -9.262, "52WeekChange": 3.7103348, "SandP52WeekChange": 0.40128052, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "DYN", "underlyingSymbol": "DYN", "shortName": "Dyne Therapeutics, Inc.", "longName": "Dyne Therapeutics, Inc.", "firstTradeDateEpochUtc": 1600349400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "bf98e34f-5989-3e23-b14d-e7c60952a6b7", "messageBoardId": "finmb_608699906", "gmtOffSetMilliseconds": -14400000, "currentPrice": 32.36, "targetHighPrice": 66.0, "targetLowPrice": 35.0, "targetMeanPrice": 52.2, "targetMedianPrice": 52.5, "recommendationMean": 1.6, "recommendationKey": "buy", "numberOfAnalystOpinions": 10, "totalCash": 778838016, "totalCashPerShare": 7.757, "ebitda": -269465984, "totalDebt": 25717000, "quickRatio": 26.177, "currentRatio": 26.63, "debtToEquity": 3.317, "returnOnAssets": -0.31454, "returnOnEquity": -0.52459997, "freeCashflow": -130435624, "operatingCashflow": -219012992, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-10-24"}]